YORVIPATH

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, United States

Active ingredients

The drug YORVIPATH contains one active pharmaceutical ingredient (API):

1 Palopegteriparatide UNII G2N64C3385 - PALOPEGTERIPARATIDE

Palopegteriparatide is a prodrug, consisting of PTH conjugated to a methoxypolyethylene glycol carrier (mPEG) via a proprietary TransCon Linker. PTH and its main metabolite, PTH, have similar affinity to and activation of PTH1R as endogenous PTH. At physiological conditions, PTH is cleaved from palopegteriparatide in a controlled manner to provide a continuous systemic exposure of active PTH. Read about Palopegteriparatide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YORVIPATH Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H05AA05		H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3058691, 3058703, 3058714
Country: IT	Agenzia del Farmaco	Identifier(s): 050966011, 050966023, 050966035
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098161, 1098162, 1098163
Country: US	FDA, National Drug Code	Identifier(s): 73362-100, 73362-101, 73362-102